Sei Investments Co. Has $13.68 Million Position in Kiniksa Pharmaceuticals International, plc $KNSA

Sei Investments Co. boosted its position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 30.6% in the 1st quarter, HoldingsChannel.com reports. The firm owned 284,005 shares of the company’s stock after buying an additional 66,509 shares during the period. Sei Investments Co.’s holdings in Kiniksa Pharmaceuticals International were worth $13,675,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. First Trust Advisors LP lifted its holdings in shares of Kiniksa Pharmaceuticals International by 3.1% during the first quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock worth $476,000 after buying an additional 293 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Kiniksa Pharmaceuticals International by 18.8% in the first quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock valued at $39,086,000 after acquiring an additional 128,417 shares during the period. KBC Group NV acquired a new position in shares of Kiniksa Pharmaceuticals International in the first quarter valued at about $34,000. Swiss National Bank grew its stake in shares of Kiniksa Pharmaceuticals International by 4.2% in the first quarter. Swiss National Bank now owns 71,500 shares of the company’s stock valued at $3,443,000 after acquiring an additional 2,900 shares in the last quarter. Finally, Precision Wealth Strategies LLC bought a new position in Kiniksa Pharmaceuticals International during the first quarter worth about $677,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have weighed in on KNSA. Weiss Ratings upgraded shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. Citigroup raised their target price on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday. The Goldman Sachs Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday. Zacks Research upgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, June 17th. Finally, Canaccord Genuity Group increased their price target on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating and nine have assigned a Buy rating to the company. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has an average rating of “Buy” and a consensus price target of $87.38.

Kiniksa Pharmaceuticals International Stock Performance

Kiniksa Pharmaceuticals International stock opened at $78.20 on Friday. Kiniksa Pharmaceuticals International, plc has a 52 week low of $29.90 and a 52 week high of $82.94. The stock has a market capitalization of $6.02 billion, a P/E ratio of 80.62 and a beta of 0.07. The stock has a fifty day moving average of $58.62 and a 200-day moving average of $50.96.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, meeting the consensus estimate of $0.30. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%.The business had revenue of $243.60 million for the quarter, compared to analyst estimates of $226.49 million. On average, research analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.39 earnings per share for the current year.

More Kiniksa Pharmaceuticals International News

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Multiple analysts raised price targets: Goldman Sachs increased its target to $90 and initiated a “buy” rating; JPMorgan raised its target to $107 with an “overweight” rating; Canaccord Genuity lifted its target to $98 and maintained a “buy” rating; Wedbush raised its target to $99 with an “outperform” rating; and Citi increased its target to $100 with a “buy” rating. The broad upward revisions signal growing confidence in KNSA’s commercial outlook and pipeline. Benzinga analyst price-target reports
• Positive Sentiment: Higher earnings estimates could support additional gains. Zacks reported that analysts are raising estimates for Kiniksa, a trend that often reflects improving expectations for future revenue and profitability. Zacks earnings estimates article
• Positive Sentiment: Raised 2026 guidance and pipeline progress drove the initial rally. Coverage highlighted Kiniksa’s stronger revenue outlook and advancement of its development pipeline, reinforcing expectations for continued growth. Yahoo Finance guidance and pipeline article
• Positive Sentiment: Quarterly results exceeded revenue expectations. Kiniksa reported $243.6 million in revenue versus the $226.5 million consensus estimate, while adjusted EPS of $0.30 matched expectations. Kalkine Media Kiniksa earnings announcement
• Negative Sentiment: Valuation is a risk after the sharp advance. One analysis suggested KNSA could be approximately 16% overvalued even after the guidance increase, potentially limiting upside or prompting profit-taking if growth expectations moderate. Yahoo Finance KNSA valuation article

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.